Research & Development
JanOne implements manufacturing contract for formulation and manufacturing of TV1001SR
7 February 2020 -

It was reported on Thursday that JanOne Inc (NASDAQ: JAN), a pharmaceutical company focused on pain reduction treatments, has begun a contract to manufacture TV1001SR, a treatment for Peripheral Artery Disease.

The product aims to address the underlying cause of Peripheral Artery Disease and associated pain, as a potential alternative to opioids.

Tony Giordano, PhD, JanOne's chief scientific officer, said, 'CoreRx's extensive clinical development experience and capabilities made them a natural choice for phase 2b formulation and manufacturing. As we finalize our clinical protocols for FDA submission and enter the next phase of trials for what we believe could be an effective PAD treatment, CoreRx is a proven partner with exceptional quality controls.'

Login
Username:

Password:


Related Headlines

US FDA approves three drugs for non-prescription or over-the-counter use

PharmaMar and Jazz Pharmaceuticals partnership files NDA for Lurbinectedin for treating relapsed SCLC

Epizyme files TAZVERIK NDA under FDA's Priority Review for follicular lymphoma

Vifor Pharma acquires PRV from the US FDA

Mycovia Pharmaceuticals Initiates Extension Clinical Studies to Further Evaluate Long-Term Efficacy of Oteseconazole in Patients with Recurrent Vulvovaginal Candidiasis

Astex Pharmaceuticals Wins US Food and Drug Administration Acceptance for Review of an NDA for the Combination Oral Hypomethylating Agent Cedazuridine and Decitabine (ASTX727 or oral C-DEC), for the Treatment of MDS and CMML

US Merck's Keytruda in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment for Metastatic Triple-Negative Breast Cancer

Elicio Therapeutics, Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002

INVO Bioscience names new vice president of Medical Affairs

Last Patient Last Visit in Cyclo Therapeutics' Phase I Trial in Niemann-Pick Type C

Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes

Elanco to divest EEA and UK rights to Drontal and Profender

Incyte Gains Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer

FDA Clears Meitheal Pharmaceuticals' Parent for Additional Manufacturing Capacity and Future Facility Expansion Plans for Production of Heparin Sodium Injection, USP

Biodesix Initiates Clinical Phase Biomarker Development Programme with German Merck and Pfizer